BridgeBio Pharma, Inc. — Director's Dealing 2021

Feb 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-02-10

Reporting Person: STEPHENSON BRIAN C (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-10	Stock Option (Right to Buy)	$68.87	A	73440	Acquired	2031-02-09	Common Stock (73440)	Direct
2021-02-10	Restricted Stock Units	$	A	12449	Acquired		Common Stock (12449)	Direct

Footnotes

F1: The option will vest in 48 equal month installments after February 10, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.

F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The units will vest in 16 equal quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.